A double-blind, randomized, placebo-controlled, multi-center, dose escalation study of a single intravenous infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in the treatment of biologic-naive patients with rheumatoid arthritis

Trial Profile

A double-blind, randomized, placebo-controlled, multi-center, dose escalation study of a single intravenous infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in the treatment of biologic-naive patients with rheumatoid arthritis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Aug 2014

At a glance

  • Drugs Rexlemestrocel-L (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Mesoblast
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Feb 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top